Home / NIH / Medicinal and Botanical Manufacturing / Notice

Reagent Generation for Bioanalytical Method Development on Biologics Therapeutics

Updated

Sources Sought from the National Institutes of Health, for work in Bethesda, Maryland. Due Nov 30, 2026, 11:00 AM (UTC-5), 13 days left.

Be among the first to see new Medicinal and Botanical Manufacturing contracts
Only new notices that match, once a day.
Solicitation number75N98027R00020
AgencyNational Institutes of Health
OfficeNational Institutes of Health Nida
Notice typeSources Sought
Set-asideNone
Trade (NAICS)Medicinal and Botanical Manufacturing (325411)
Product or service codeAN11
Place of performanceBethesda, Maryland
PostedNov 16, 2026
Response deadlineNov 30, 2026, 11:00 AM (UTC-5) (13 days left)
Add the deadline toGoogle Calendar · Apple / Outlook (.ics)
Official notice
Send to a teammate

Bid documents (1)

Paid members download every document from this page, or buy this bid alone.

Federal prevailing wage rates for this place: Maryland Davis-Bacon and SCA wage determinations.

Description

Title: Reagent Generation for Bioanalytical Method Development on Biologics Therapeutics This is a Sources Sought notice. This is NOT a solicitation for proposals, proposal abstracts, or quotations. The purpose of this notice is to obtain information regarding the availability and capability of all qualified sources to perform a potential requirement.

This notice is issued to help determine the availability of qualified companies technically capable of meeting the Government requirement and to determine the method of acquisition. It is not to be construed as a commitment by the Government to issue a solicitation or ultimately award a contract. Responses will not be considered as proposals or quotes.

No award will be made as a result of this notice. The Government will NOT be responsible for any costs incurred by the respondents to this notice. This notice is strictly for research and information purposes only.

The Government is especially interested in determining (1) the availability of qualified small business sources; (2) whether they are small businesses; HUBZone small businesses; service-disabled, veteran-owned small businesses; 8(a) small businesses; veteran-owned small businesses; woman-owned small businesses; or small disadvantaged businesses; and (3) their size classification relative to the North American Industry Classification System (NAICS) code for the proposed acquisition (5) commercial product and services availability.

Your responses to the information requested will assist the Government in determining the appropriate acquisition method, including whether a set-aside is possible. Background: The Therapeutic Development Branch (TDB) within the Division of Preclinical Innovation (DPI) at National Center for Advancing Translational Sciences (NCATS), National Institutes of Health (NIH) conducts translational research in the area of human therapeutics development by moving small molecule and biologic drug candidates forward in the drug development pipeline.

Upon reaching predetermined milestones, TDB hands off clinical candidates to external partners to bring these novel therapies to patients. In addition to developing new candidate drugs, TDB seeks to advance the entire field of drug discovery and development by encouraging scientific and technological innovations aimed at improving success rates in the crucial preclinical stage of drug development.

The TDB model is to operate as a comprehensive small molecule and biologics drug development organization, moving therapeutic candidates through each phase of the preclinical development process until an Investigational New Drug (IND) application is filed with the US Food and Drug Administration (FDA). TDB conducts drug development as collaborations, with therapeutic candidates originating from academia, industry, non- profit foundations, or internally from NCATS and other NIH Institutes and Centers.

TDB’s operational strategy is to combine the capabilities of in-house staff and collaborative partners with complementary support from contract research organizations (CROs). Each development program operates in a multi-disciplinary matrix team environment, with NCATS responsible for the overall planning and execution. Please see the attachment for more details.

Contracting contact

As published on the official notice. Ask questions in writing and before any questions deadline the notice sets.

Is your business small enough?

For NAICS 325411, a business counts as small if it has no more than 1,000 employees (SBA size standard). This notice is not set aside, but the size decides your small business status on it. SBA table, current as of Oct 15, 2026.

Companies that win this kind of work

Federal contractors paid for medicinal and botanical manufacturing work, who also hold NIH contracts (last 12 months): possible competitors, or partners to team with.

About the buyer

The National Institutes of Health awarded $5.9 billion in contracts in the last 12 months; its biggest suppliers were Leidos Biomedical Research Inc, M. A. Mortenson Company and Deloitte Consulting LLP. See what NIH is buying now.